^
Association details:
| Biomarker: | ERBB3 expression |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | AMT-562 (Topoisomerase I inhibitor, HER3-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
AMT-562, a novel HER3-targeting antibody drug conjugate, demonstrates a potential to broaden therapeutic opportunities for HER3-expressing tumors
Published date:
06/11/2023
Excerpt:
AMT-562 showed potent and durable antitumor response in low HER3 expression xenograft and heterogeneous patient-derived xenograft/organoid (PDX/PDO) models, including digestive system and lung tumors representing of unmet needs….AMT-562 has potential to be a superior HER3-targeting ADC with a higher therapeutic window that can overcome resistance to generate higher percentage and more durable responses in U3-1402-insensitive tumors.
DOI:
https://doi.org/10.1158/1535-7163.MCT-23-0198
